Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types

Craig P. Giacomini, Steven Sun, Sushama Varma, A. Hunter Shain, Marilyn M. Giacomini, Jay Balagtas, Robert T. Sweeney, Everett Lai, Catherine A. Del Vecchio, Andrew D. Forster, Nicole Clarke, Kelli D. Montgomery, Shirley Zhu, Albert J. Wong, Matt van de Rijn, Robert B. West, Jonathan R. Pollack

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Gene fusions, like BCR/ABL1 in chronic myelogenous leukemia, have long been recognized in hematologic and mesenchymal malignancies. The recent finding of gene fusions in prostate and lung cancers has motivated the search for pathogenic gene fusions in other malignancies. Here, we developed a "breakpoint analysis" pipeline to discover candidate gene fusions by tell-tale transcript level or genomic DNA copy number transitions occurring within genes. Mining data from 974 diverse cancer samples, we identified 198 candidate fusions involving annotated cancer genes. From these, we validated and further characterized novel gene fusions involving ROS1 tyrosine kinase in angiosarcoma (CEP85L/ROS1), SLC1A2 glutamate transporter in colon cancer (APIP/SLC1A2), RAF1 kinase in pancreatic cancer (ATG7/RAF1) and anaplastic astrocytoma (BCL6/RAF1), EWSR1 in melanoma (EWSR1/CREM), CDK6 kinase in T-cell acute lymphoblastic leukemia (FAM133B/CDK6), and CLTC in breast cancer (CLTC/VMP1). Notably, while these fusions involved known cancer genes, all occurred with novel fusion partners and in previously unreported cancer types. Moreover, several constituted druggable targets (including kinases), with therapeutic implications for their respective malignancies. Lastly, breakpoint analysis identified new cell line models for known rearrangements, including EGFRvIII and FIP1L1/PDGFRA. Taken together, we provide a robust approach for gene fusion discovery, and our results highlight a more widespread role of fusion genes in cancer pathogenesis.

Original languageEnglish (US)
Article numbere1003464
JournalPLoS Genetics
Volume9
Issue number4
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

gene fusion
Gene Fusion
cancer
genomics
neoplasms
gene
Neoplasm Genes
phosphotransferases (kinases)
Neoplasms
Phosphotransferases
Excitatory Amino Acid Transporter 2
Amino Acid Transport System X-AG
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
pancreatic neoplasms
lymphocytic leukemia
Hemangiosarcoma
Data Mining
genes
Astrocytoma
Genetic Association Studies

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Ecology, Evolution, Behavior and Systematics
  • Cancer Research
  • Genetics(clinical)

Cite this

Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J., ... Pollack, J. R. (2013). Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types. PLoS Genetics, 9(4), [e1003464]. https://doi.org/10.1371/journal.pgen.1003464

Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types. / Giacomini, Craig P.; Sun, Steven; Varma, Sushama; Shain, A. Hunter; Giacomini, Marilyn M.; Balagtas, Jay; Sweeney, Robert T.; Lai, Everett; Del Vecchio, Catherine A.; Forster, Andrew D.; Clarke, Nicole; Montgomery, Kelli D.; Zhu, Shirley; Wong, Albert J.; van de Rijn, Matt; West, Robert B.; Pollack, Jonathan R.

In: PLoS Genetics, Vol. 9, No. 4, e1003464, 04.2013.

Research output: Contribution to journalArticle

Giacomini, CP, Sun, S, Varma, S, Shain, AH, Giacomini, MM, Balagtas, J, Sweeney, RT, Lai, E, Del Vecchio, CA, Forster, AD, Clarke, N, Montgomery, KD, Zhu, S, Wong, AJ, van de Rijn, M, West, RB & Pollack, JR 2013, 'Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types', PLoS Genetics, vol. 9, no. 4, e1003464. https://doi.org/10.1371/journal.pgen.1003464
Giacomini, Craig P. ; Sun, Steven ; Varma, Sushama ; Shain, A. Hunter ; Giacomini, Marilyn M. ; Balagtas, Jay ; Sweeney, Robert T. ; Lai, Everett ; Del Vecchio, Catherine A. ; Forster, Andrew D. ; Clarke, Nicole ; Montgomery, Kelli D. ; Zhu, Shirley ; Wong, Albert J. ; van de Rijn, Matt ; West, Robert B. ; Pollack, Jonathan R. / Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types. In: PLoS Genetics. 2013 ; Vol. 9, No. 4.
@article{0ea9150790b046609449cad38a4728ad,
title = "Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types",
abstract = "Gene fusions, like BCR/ABL1 in chronic myelogenous leukemia, have long been recognized in hematologic and mesenchymal malignancies. The recent finding of gene fusions in prostate and lung cancers has motivated the search for pathogenic gene fusions in other malignancies. Here, we developed a {"}breakpoint analysis{"} pipeline to discover candidate gene fusions by tell-tale transcript level or genomic DNA copy number transitions occurring within genes. Mining data from 974 diverse cancer samples, we identified 198 candidate fusions involving annotated cancer genes. From these, we validated and further characterized novel gene fusions involving ROS1 tyrosine kinase in angiosarcoma (CEP85L/ROS1), SLC1A2 glutamate transporter in colon cancer (APIP/SLC1A2), RAF1 kinase in pancreatic cancer (ATG7/RAF1) and anaplastic astrocytoma (BCL6/RAF1), EWSR1 in melanoma (EWSR1/CREM), CDK6 kinase in T-cell acute lymphoblastic leukemia (FAM133B/CDK6), and CLTC in breast cancer (CLTC/VMP1). Notably, while these fusions involved known cancer genes, all occurred with novel fusion partners and in previously unreported cancer types. Moreover, several constituted druggable targets (including kinases), with therapeutic implications for their respective malignancies. Lastly, breakpoint analysis identified new cell line models for known rearrangements, including EGFRvIII and FIP1L1/PDGFRA. Taken together, we provide a robust approach for gene fusion discovery, and our results highlight a more widespread role of fusion genes in cancer pathogenesis.",
author = "Giacomini, {Craig P.} and Steven Sun and Sushama Varma and Shain, {A. Hunter} and Giacomini, {Marilyn M.} and Jay Balagtas and Sweeney, {Robert T.} and Everett Lai and {Del Vecchio}, {Catherine A.} and Forster, {Andrew D.} and Nicole Clarke and Montgomery, {Kelli D.} and Shirley Zhu and Wong, {Albert J.} and {van de Rijn}, Matt and West, {Robert B.} and Pollack, {Jonathan R.}",
year = "2013",
month = "4",
doi = "10.1371/journal.pgen.1003464",
language = "English (US)",
volume = "9",
journal = "PLoS Genetics",
issn = "1553-7390",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types

AU - Giacomini, Craig P.

AU - Sun, Steven

AU - Varma, Sushama

AU - Shain, A. Hunter

AU - Giacomini, Marilyn M.

AU - Balagtas, Jay

AU - Sweeney, Robert T.

AU - Lai, Everett

AU - Del Vecchio, Catherine A.

AU - Forster, Andrew D.

AU - Clarke, Nicole

AU - Montgomery, Kelli D.

AU - Zhu, Shirley

AU - Wong, Albert J.

AU - van de Rijn, Matt

AU - West, Robert B.

AU - Pollack, Jonathan R.

PY - 2013/4

Y1 - 2013/4

N2 - Gene fusions, like BCR/ABL1 in chronic myelogenous leukemia, have long been recognized in hematologic and mesenchymal malignancies. The recent finding of gene fusions in prostate and lung cancers has motivated the search for pathogenic gene fusions in other malignancies. Here, we developed a "breakpoint analysis" pipeline to discover candidate gene fusions by tell-tale transcript level or genomic DNA copy number transitions occurring within genes. Mining data from 974 diverse cancer samples, we identified 198 candidate fusions involving annotated cancer genes. From these, we validated and further characterized novel gene fusions involving ROS1 tyrosine kinase in angiosarcoma (CEP85L/ROS1), SLC1A2 glutamate transporter in colon cancer (APIP/SLC1A2), RAF1 kinase in pancreatic cancer (ATG7/RAF1) and anaplastic astrocytoma (BCL6/RAF1), EWSR1 in melanoma (EWSR1/CREM), CDK6 kinase in T-cell acute lymphoblastic leukemia (FAM133B/CDK6), and CLTC in breast cancer (CLTC/VMP1). Notably, while these fusions involved known cancer genes, all occurred with novel fusion partners and in previously unreported cancer types. Moreover, several constituted druggable targets (including kinases), with therapeutic implications for their respective malignancies. Lastly, breakpoint analysis identified new cell line models for known rearrangements, including EGFRvIII and FIP1L1/PDGFRA. Taken together, we provide a robust approach for gene fusion discovery, and our results highlight a more widespread role of fusion genes in cancer pathogenesis.

AB - Gene fusions, like BCR/ABL1 in chronic myelogenous leukemia, have long been recognized in hematologic and mesenchymal malignancies. The recent finding of gene fusions in prostate and lung cancers has motivated the search for pathogenic gene fusions in other malignancies. Here, we developed a "breakpoint analysis" pipeline to discover candidate gene fusions by tell-tale transcript level or genomic DNA copy number transitions occurring within genes. Mining data from 974 diverse cancer samples, we identified 198 candidate fusions involving annotated cancer genes. From these, we validated and further characterized novel gene fusions involving ROS1 tyrosine kinase in angiosarcoma (CEP85L/ROS1), SLC1A2 glutamate transporter in colon cancer (APIP/SLC1A2), RAF1 kinase in pancreatic cancer (ATG7/RAF1) and anaplastic astrocytoma (BCL6/RAF1), EWSR1 in melanoma (EWSR1/CREM), CDK6 kinase in T-cell acute lymphoblastic leukemia (FAM133B/CDK6), and CLTC in breast cancer (CLTC/VMP1). Notably, while these fusions involved known cancer genes, all occurred with novel fusion partners and in previously unreported cancer types. Moreover, several constituted druggable targets (including kinases), with therapeutic implications for their respective malignancies. Lastly, breakpoint analysis identified new cell line models for known rearrangements, including EGFRvIII and FIP1L1/PDGFRA. Taken together, we provide a robust approach for gene fusion discovery, and our results highlight a more widespread role of fusion genes in cancer pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84876882782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876882782&partnerID=8YFLogxK

U2 - 10.1371/journal.pgen.1003464

DO - 10.1371/journal.pgen.1003464

M3 - Article

VL - 9

JO - PLoS Genetics

JF - PLoS Genetics

SN - 1553-7390

IS - 4

M1 - e1003464

ER -